Navigation Links
Acute Ischemic Stroke Drug Market Will Remain Relatively Flat, Increasing From $360 Million in 2008 to $450 Million in 2018
Date:11/17/2009

WALTHAM, Mass., Nov. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of agents to treat acute ischemic stroke will remain relatively flat over the next decade, increasing from $360 million in 2008 to $450 million in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Acute Ischemic Stroke finds that broadening the use of the recombinant tissue plasminogen activator (rt-PA; Genentech's Activase, other brands) and innovative therapies like stroke devices, such as Concentric Medical's Merci Retrieval System, will be important near-term advancements in the treatment of this indication. According to the report, drug-treatment rates for acute ischemic stroke will fluctuate modestly as the use of thrombolysis gradually increases, aided by continued improvements in stroke care throughout the major pharmaceutical markets.

Activase is now recommended for intravenous administration within 4.5 hours of stroke onset , as a result of recent positive clinical trial results from the third European Cooperative Acute Stroke Study (ECASS III). The report finds that the slowly expanding use of Activase will contribute to a modestly growing market through 2018, but a variety of limiting factors will continue to constrain the adoption of this and other time-sensitive treatments, and the promise of emerging therapies for acute ischemic stroke remains highly uncertain.

"In light of the recent discontinuations of several clinical-stage products, the stroke market continues to be a graveyard for drug development," said Decision Resources Analyst Jonathan Searles, B.A. "While drug developers continue to investigate novel therapies to expand the stroke armamentarium, interviewed experts express their lingering doubts about the clinical potential of late-stage compo
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... LEHIGH VALLEY, Pa. , July 28, 2014 /PRNewswire/ ... a reliable, uninterrupted supply of medical oxygen is vital ... company to technical innovations that not only improve the ... gas use. Air Products will highlight these systems—including systems ... systems that reduce oxygen loss—from August 4-5 at the ...
(Date:7/28/2014)... 28, 2014  Array BioPharma Inc. (Nasdaq:   ... fourth quarter and full year of fiscal ... discuss those results on Tuesday, August 12, ... Michael Carruthers , Chief Financial Officer ... 12, 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass ...
(Date:7/28/2014)... -- Houston dentist , Dr. Behzad Nazari ... Invisalign. With access to this increasingly popular orthodontic ... without feeling self-conscious in the process. Invisalign offers ... of braces, but patients who choose Invisalign over ... support for their oral health and comfort during ...
Breaking Medicine Technology:Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 2Air Products Highlights Its Medical Oxygen Supply Systems for Emergency Oxygen Supply and Reduced Oxygen Loss at ASHE 3Houston Cosmetic Dentist, Dr. Behzad Nazari, Now Offers Orthodontic Treatment with Invisalign 2
... Reportlinker.com announces that a new market research ... The Outlook for Medical ... http://www.reportlinker.com/p0192649/The-Outlook-for-Medical-Devices-in-South-East-Asia.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care ... the Middle East is published by Espicom ...
... Belt Technologies, Inc., a medical device company focused ... providing precise robotic control for use initially in ... including neurosurgery, spinal and otolaryngology ("NET"), announced today ... partial knee replacements will be featured at the ...
Cached Medicine Technology:The Outlook for Medical Devices in South East Asia 2The Outlook for Medical Devices in South East Asia 3The Outlook for Medical Devices in South East Asia 4The Outlook for Medical Devices in South East Asia 5Blue Belt Technologies to Showcase Navio™ PFS System at CAOS UK 2012 Conference in Glasgow, UK 2
(Date:7/28/2014)... St. Jude Children’s Research Hospital ... of Defense Employer Support Freedom Award from the Employer Support ... Defense. The award is the highest honor given by the ... who serve in the National Guard and Reserve. , “We ... their contributions to the St. Jude mission and to our ...
(Date:7/28/2014)... possible by a test developed at University of Colorado ... of Pharmacy), AURORA, Colo (July 28, 2014) An influential ... Pharmacology Laboratory at the CU School of Pharmacy, helps ... Truvada (a combination of tenofovir/emtricitabine), which is taken once ... presented during the AIDS 2014 Conference and published in ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 The ... Lipase), Applications (Food & Beverages, Cleaning Agents, Bio-Fuel, ... Forecasts to 2018” defines and segments the global ... the global value for industrial enzymes. It also ... industrial enzymes market with analysis of trends, opportunities, ...
(Date:7/28/2014)... 2014 Qualis Health, one of ... organizations, has published a complimentary, online toolkit that ... patients and families in infection control. Tested ... the toolkit provides a step-by-step roadmap for implementing ... their families early in a hospital stay. , ...
(Date:7/28/2014)... Dennis Thompson HealthDay ... -- Babies born prematurely appear to have a slightly ... will carry into adulthood, Swedish researchers report. Doctors ... weeks, gestation have a raised risk of deep vein ... blood clotting in the veins, the researchers noted in ...
Breaking Medicine News(10 mins):Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 2Health News:St. Jude Children’s Research Hospital Receives Secretary of Defense Employer Support Freedom Award 3Health News:HIV research findings made possible by a test developed at CU School of Pharmacy 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 2Health News:Preemies May Have Higher Risk of Blood Clots, Even as Adults 3
... a team of researchers an expression pattern of certain ... in lunch cancer patients.// ,The analysis of these ... of diagnostic and prognostic tools for lung cancer. ... Ohio; the Jikei University School of Medicine, Tokyo, Japan; ...
... for the final hearing of India's biggest ever medical compensation ... in a woman's death eight years ago.// ,"I ... again be postponed by the machinations of my opponents," Ohio-based ... of the final hearing at the National Consumer Disputes Redressal ...
... Welfare has said that measures taken to check the ... sums in public health expenditure. // Preventive Health Initiatives ... to statistics, these spending are just $68 a year ... $77 million was expended on public health programs in ...
... rendered to Scotland children, could soon come to an end, ... by ministers. // Dental practices in Scotland yield a considerable ... of registered NHS patients. ,There exists a flaw ... extra payments, says the British Dental Association (BDA). This could ...
... Health Service has conducted a study and found that the rates ... , More parents are getting their children immunized with the ... below the Scottish Executive's target level of 95% by the age ... of immunization. The drop was due to the vaccines association with ...
... soon be launched for commercial use in Hungary following ... Minister, Ferenc Gyurcsany, made the announcement. ,Hungary ... year. Vaccine trials conducted on animal and human models ... claimed to confer protection against the H5N1 virus that ...
Cached Medicine News:Health News:Lung cancer molecular profile discovered by researchers. 2Health News:Stage Set For Final Hearing On India’s Biggest Ever Medical Compensation Clai 2Health News:Children In Scotland Denied Access To Dental Care 2